ATE240395T1 - Antikörper gegen e-selektin - Google Patents

Antikörper gegen e-selektin

Info

Publication number
ATE240395T1
ATE240395T1 AT95913225T AT95913225T ATE240395T1 AT E240395 T1 ATE240395 T1 AT E240395T1 AT 95913225 T AT95913225 T AT 95913225T AT 95913225 T AT95913225 T AT 95913225T AT E240395 T1 ATE240395 T1 AT E240395T1
Authority
AT
Austria
Prior art keywords
antibodies
selectin
antibodies against
complement
receptors
Prior art date
Application number
AT95913225T
Other languages
English (en)
Inventor
Raymond John Owens
Martyn Kim Robinson
Original Assignee
Celltech Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB9406243A external-priority patent/GB9406243D0/en
Priority claimed from GB9415331A external-priority patent/GB9415331D0/en
Application filed by Celltech Therapeutics Ltd filed Critical Celltech Therapeutics Ltd
Application granted granted Critical
Publication of ATE240395T1 publication Critical patent/ATE240395T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
    • C07K16/465—Igs containing CDR-residues from one specie grafted between FR-residues from another with additional modified FR-residues
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C07K16/2854—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72 against selectins, e.g. CD62
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Rheumatology (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
AT95913225T 1994-03-29 1995-03-28 Antikörper gegen e-selektin ATE240395T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9406243A GB9406243D0 (en) 1994-03-29 1994-03-29 Antibodies
GB9415331A GB9415331D0 (en) 1994-07-29 1994-07-29 Antibodies
PCT/GB1995/000692 WO1995026403A1 (en) 1994-03-29 1995-03-28 Antibodies against e-selectin

Publications (1)

Publication Number Publication Date
ATE240395T1 true ATE240395T1 (de) 2003-05-15

Family

ID=26304600

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95913225T ATE240395T1 (de) 1994-03-29 1995-03-28 Antikörper gegen e-selektin

Country Status (10)

Country Link
US (2) US6204007B1 (de)
EP (1) EP0753065B1 (de)
JP (1) JPH09512705A (de)
AT (1) ATE240395T1 (de)
AU (1) AU707440B2 (de)
CA (1) CA2186455A1 (de)
DE (1) DE69530763T2 (de)
GB (1) GB2301366B (de)
NZ (1) NZ282849A (de)
WO (1) WO1995026403A1 (de)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU707440B2 (en) * 1994-03-29 1999-07-08 Celltech Therapeutics Limited Antibodies against E-selectin
US5962424A (en) * 1995-02-21 1999-10-05 Arch Development Corporation Methods and compositions for targeting selectins
AU6155896A (en) * 1995-06-07 1996-12-30 Cytel Corporation Humanized antibodies to e-selectin
US6900292B2 (en) * 2001-08-17 2005-05-31 Lee-Hwei K. Sun Fc fusion proteins of human erythropoietin with increased biological activities
US6797493B2 (en) 2001-10-01 2004-09-28 Lee-Hwei K. Sun Fc fusion proteins of human granulocyte colony-stimulating factor with increased biological activities
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US8188231B2 (en) 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
US7662925B2 (en) 2002-03-01 2010-02-16 Xencor, Inc. Optimized Fc variants and methods for their generation
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
ATE483472T1 (de) 2002-05-30 2010-10-15 Macrogenics Inc Cd16a bindungsproteine und verwendung zur behandlung von immunkrankheiten
CA2506629A1 (en) * 2002-11-27 2004-06-17 Gtc Biotherapeutics, Inc. Modified antibodies stably produced in milk and methods of producing same
US8388955B2 (en) 2003-03-03 2013-03-05 Xencor, Inc. Fc variants
US20090010920A1 (en) 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
US8084582B2 (en) 2003-03-03 2011-12-27 Xencor, Inc. Optimized anti-CD20 monoclonal antibodies having Fc variants
US9051373B2 (en) 2003-05-02 2015-06-09 Xencor, Inc. Optimized Fc variants
US9714282B2 (en) 2003-09-26 2017-07-25 Xencor, Inc. Optimized Fc variants and methods for their generation
US8101720B2 (en) 2004-10-21 2012-01-24 Xencor, Inc. Immunoglobulin insertions, deletions and substitutions
CN1922316B (zh) 2003-12-25 2011-03-23 协和发酵麒麟株式会社 抗cd40抗体突变体
EP1737890A2 (de) 2004-03-24 2007-01-03 Xencor, Inc. Immunoglobulinvarianten ausserhalb der fc-region
PT1737891E (pt) 2004-04-13 2013-04-16 Hoffmann La Roche Anticorpos anti p-selectina
US20150010550A1 (en) 2004-07-15 2015-01-08 Xencor, Inc. OPTIMIZED Fc VARIANTS
US20060020246A1 (en) * 2004-07-22 2006-01-26 Mclucas Bruce Angiographic catheter for uterine artery embolization
US8802820B2 (en) 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
US8546543B2 (en) 2004-11-12 2013-10-01 Xencor, Inc. Fc variants that extend antibody half-life
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
AU2005304624B2 (en) 2004-11-12 2010-10-07 Xencor, Inc. Fc variants with altered binding to FcRn
US20080019905A9 (en) * 2005-02-18 2008-01-24 Strome Scott E Method of using an anti-CD137 antibody as an agent for radioimmunotherapy or radioimmunodetection
US20110123440A1 (en) * 2005-03-29 2011-05-26 Genevieve Hansen Altered Antibody FC Regions and Uses Thereof
WO2007041635A2 (en) 2005-10-03 2007-04-12 Xencor, Inc. Fc variants with optimized fc receptor binding properties
WO2007044616A2 (en) 2005-10-06 2007-04-19 Xencor, Inc. Optimized anti-cd30 antibodies
KR20140133958A (ko) * 2005-10-21 2014-11-20 엘에프비 유에스에이, 인크. 항체 의존성 세포 독성 활성이 증강된 항체, 그 생산 및 사용 방법
PL2383297T3 (pl) 2006-08-14 2013-06-28 Xencor Inc Zoptymalizowane przeciwciała ukierunkowane na CD19
WO2008036688A2 (en) 2006-09-18 2008-03-27 Xencor, Inc. Optimized antibodies that target hm1.24
CN105037549B (zh) * 2007-01-11 2018-09-28 诺和诺德公司 抗-kir抗体、制剂及其应用
JP2010235447A (ja) * 2007-07-30 2010-10-21 Igaku Seibutsugaku Kenkyusho:Kk 炎症性サイトカインの抑制剤
WO2009073911A1 (en) 2007-12-10 2009-06-18 Mater Medical Research Institute Treatment and prophylaxis
EP2235536A4 (de) 2007-12-20 2011-05-04 Lab Corp America Holdings Her-2-diagnoseverfahren
HRP20150279T1 (hr) 2007-12-26 2015-05-08 Xencor, Inc. Fc inaäśice s promijenjenim vezanjem na fcrn
US12492253B1 (en) 2008-02-25 2025-12-09 Xencor, Inc. Anti-human C5 antibodies
EP2279003A4 (de) * 2008-05-01 2013-04-03 Gtc Biotherapeutics Inc Anti-cd137-antikörper als mittel zur behandlung von entzündlichen erkrankungen
ES2637411T3 (es) 2008-12-01 2017-10-13 Laboratory Corporation Of America Holdings Métodos y ensayos para medir p95 Y/O p95 en una muestra y anticuerpos específicos para p95
EP2387711B1 (de) * 2009-01-15 2015-04-22 Laboratory Corporation of America Holdings Verfahren zur bestimmung von patientenreaktionen durch her-3-messung
JP2012515353A (ja) * 2009-01-15 2012-07-05 ラボラトリー コーポレイション オブ アメリカ ホールディングス Ｈｅｒ−２発現の測定による患者の反応を判定する方法
WO2011028952A1 (en) 2009-09-02 2011-03-10 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
WO2011091078A2 (en) 2010-01-19 2011-07-28 Xencor, Inc. Antibody fc variants with enhanced complement activity
WO2012142411A1 (en) * 2011-04-15 2012-10-18 Clavis Pharma Asa Systems and methods for detecting hent1 expression in hematological disorders
EP3758715B1 (de) 2018-03-02 2025-12-03 Peter Gillies Wirkstoffe zur hemmung der expression und/oder aktivität von p-selectin zur verwendung zur hemmung der epithelzellproliferation bei der behandlung von primärem krebs
PE20220500A1 (es) * 2019-04-23 2022-04-07 Lg Chemical Ltd POLIPEPTIDO DE FUSION QUE COMPRENDE LA REGION Fc DE INMUNOGLOBULINA Y GDF15
BR112022014417A2 (pt) 2020-01-24 2022-09-13 Pfizer Anticorpos anti-e-selectina, composições e métodos de uso
KR20230015365A (ko) 2020-05-22 2023-01-31 포르미콘 아게 Ace2 융합 단백질 및 이의 용도
KR20230093483A (ko) 2020-10-29 2023-06-27 포르미콘 아게 Ace2 융합 단백질 및 이의 용도
AU2022230745A1 (en) 2021-03-03 2023-08-17 Formycon Ag Formulations of ace2 fc fusion proteins
EP4437112A1 (de) 2021-11-24 2024-10-02 Formycon AG Verbesserte ace2-fusionsproteine
WO2023094571A1 (en) 2021-11-25 2023-06-01 Formycon Ag Stabilization of ace2 fusion proteins
US20230303719A1 (en) 2022-03-03 2023-09-28 Yale University Humanized 3e10 antibodies, variants, and antigen binding fragments thereof
JP2026502768A (ja) 2022-10-25 2026-01-27 アブレクシス， エルエルシー 抗ｃｄ３抗体
WO2024107731A2 (en) 2022-11-14 2024-05-23 Ablexis, Llc Anti-pd-l1 antibodies
EP4386084A1 (de) 2022-12-14 2024-06-19 Formycon AG Verbesserte ace2-fusionsproteine
WO2026039779A1 (en) 2024-08-15 2026-02-19 Yale University Humanized 3e10 antibodies and antigen binding fragments optimized for rad51 binding

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
JP3101690B2 (ja) * 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
AU625613B2 (en) * 1988-01-05 1992-07-16 Novartis Ag Novel chimeric antibodies
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
GB8928874D0 (en) * 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
EP0438312A3 (en) * 1990-01-19 1992-07-01 Merck & Co. Inc. Recombinant human anti-cd18 antibodies
GB9109645D0 (en) 1991-05-03 1991-06-26 Celltech Ltd Recombinant antibodies
JPH07506253A (ja) * 1992-04-30 1995-07-13 ジェネンテク，インコーポレイテッド セレクチン変異体
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
AU707440B2 (en) * 1994-03-29 1999-07-08 Celltech Therapeutics Limited Antibodies against E-selectin

Also Published As

Publication number Publication date
EP0753065B1 (de) 2003-05-14
US6204007B1 (en) 2001-03-20
JPH09512705A (ja) 1997-12-22
DE69530763T2 (de) 2004-02-26
GB2301366A (en) 1996-12-04
NZ282849A (en) 1998-05-27
EP0753065A1 (de) 1997-01-15
US6407214B1 (en) 2002-06-18
AU707440B2 (en) 1999-07-08
CA2186455A1 (en) 1995-10-05
GB9619691D0 (en) 1996-11-06
GB2301366B (en) 1998-07-29
WO1995026403A1 (en) 1995-10-05
DE69530763D1 (de) 2003-06-18
AU2076995A (en) 1995-10-17

Similar Documents

Publication Publication Date Title
ATE240395T1 (de) Antikörper gegen e-selektin
TR200102733T2 (tr) IL-18 kaynaklı rahatsızlıkların tedavisinde faydalı rekombinant IL-18 antagonistleri
CY1117387T1 (el) ΜΟΝΟΚΛΩΝΙΚΑ ΑΝΤΙΣΩΜΑΤΑ Ν-11 ΔΙΑΣΠΑΣΜΕΝΟΥ β-ΑΜΥΛΟΕΙΔΟΥΣ, ΣΥΝΘΕΣΕΙΣ, ΜΕΘΟΔΟΙ ΚΑΙ ΧΡΗΣΕΙΣ
TR199901172T2 (xx) Yeni ikame edilmi� pirazol t�revleri.
ATE517125T1 (de) ANTIKÖRPER GEGEN ßDEATH RECEPTOR 4ß (DR4) UND DEREN VERWENDUNGEN
HUP9802212A2 (hu) Humán terápiában alkalmazható rekombináns anti-CD4-ellenanyagok
TR200003281T2 (tr) CD-23'e karşı antikorlar, bunların türevleri ve terapötik kullanımları.
ES2084338T3 (es) Anticuerpos recombinantes especificos para el tnf alfa.
ATE197592T1 (de) Monoklonaler antikörper gegen cd44v6
GB2364059A (en) Beta-Secretase enzyme compositions and methods
ATE364699T1 (de) Humanisierte antikörper gegen humanes gp39, zusammensetzungen die diese enthalten und deren therapeutische verwendungen
TR200000913T2 (tr) Tıbbi maddeler
DK0670735T3 (da) Perifisering af hæmotopoietiske stamceller.
YU34196A (sh) Peptidi i jedinjenja koja se vezuju za receptor
TR199801722T2 (xx) Peptit imm�nojenler.
DK0845998T3 (da) Lægemidler til immunbehandling indeholdende antistoffer, der specifikt genkender MHCII-antigenet hos en patient, der skal behandles
DE69738613D1 (de) Prävention und behandlung von skeletterkrankungen mit ep2 subtyp selektiven prostaglandin e2 agonisten
NO20004795D0 (no) Peptidbaserte forbindelser
DE60040753D1 (de) Therapeutische verwendungen von steroiden bei blutzellmangelzustaenden
FI972703A0 (fi) Rekombinantti IL-5-antagonisteja, jotka ovat käyttökelpoisia hoidettaessa IL-5:een liittyviä sairauksia
DE69426767D1 (de) Anti idiotypische Antikörper gegen Gonococcen und diese verwendende Verfahren und Zusammensetzungen.
ATE449847T1 (de) Hepatitis c rezeptorprotein cd81
MX9101958A (es) Inhibidores de acat de urea de aminosulfonilo
CO4820397A1 (es) TRATAMIENTO CONTRA EL ASMA CON TNFR -Ig
SE8702734L (sv) Monoklonala antikroppar mot pseudomonas aeruginosa-flageller

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties